Atherosclerosis
Volume 221, Issue 2 , Pages 366-374, April 2012

Lymphangiogenesis in aortic valve stenosis—Novel regulatory roles for valvular myofibroblasts and mast cells

  • Suvi Syväranta

      Affiliations

    • Wihuri Research Institute, Kalliolinnantie 4, 00140 Helsinki, Finland
  • ,
  • Satu Helske

      Affiliations

    • Wihuri Research Institute, Kalliolinnantie 4, 00140 Helsinki, Finland
    • Division of Cardiology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
  • ,
  • Jani Lappalainen

      Affiliations

    • Wihuri Research Institute, Kalliolinnantie 4, 00140 Helsinki, Finland
  • ,
  • Markku Kupari

      Affiliations

    • Division of Cardiology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
  • ,
  • Petri T. Kovanen

      Affiliations

    • Wihuri Research Institute, Kalliolinnantie 4, 00140 Helsinki, Finland
    • Corresponding Author InformationCorresponding author. Tel.: +358 9 681 411; fax: +358 9 637 476.

Received 10 October 2011; received in revised form 6 December 2011; accepted 21 December 2011. published online 27 January 2012.

Highlights

► Lympatic vessels can be found in human stenotic aortic valves. ► Lymphangiogenic growth factors VEGF-C and VEGF-D are locally produced. ► Myofibroblasts and endothelial cells are their possible sources in aortic valves. ► Mast cells can both induce the expression of VEGF-C and degrade the protein. ► Imbalance between lymphatic and blood vessels may promote disease progression.

Abstract 

Objective

To investigate mechanisms of lymphangiogenesis in aortic valve stenosis (AS).

Methods

Lymphatic vessels were visualized with LYVE-1 staining in 20 control, 5 sclerotic, and 40 stenotic human aortic valves. Vascular endothelial growth factors (VEGFs) VEGF-C and VEGF-D, and their lymphangiogenic receptor VEGFR-3, and the angiogenic VEGFR-2 were analysed by quantitative real-time PCR and immunohistochemistry. Cultured myofibroblasts derived from human stenotic aortic valves, and cultured human mast cells were used to study VEGF-C regulation, and VEGF-C and VEGF-A were quantified from cell culture media by enzyme immunoassays.

Results

Lymphatic vessels, VEGF-C, VEGF-D, VEGFR-3 and VEGFR-2 all were present in the aortic valves. In AS, the number of lymphatic vessels and the expression of VEGF-D, VEGFR-3, and VEGFR-2 were increased. Moreover, the numbers of lymphatic vessels correlated positively with those of neovessels (r=0.525, p=0.001) and mast cells (r=0.374, p=0.017). Cultured valvular myofibroblasts produced VEGF-C, and addition of tumour necrosis factor alpha (TNF-α) to the cells augmented its secretion. In contrast, proteases released by activated human mast cells degraded VEGF-C.

Conclusion

These results show that lymphangiogenesis is induced in advancing AS. Furthermore, valvular myofibroblasts and activated mast cells were identified as novel regulators of lymphangiogenesis in aortic valves.

Keywords: Aortic valve stenosis, Lymphangiogenesis, Mast cells, Myofibroblasts, Vascular endothelial growth factor C

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0021-9150(11)01181-6

doi:10.1016/j.atherosclerosis.2011.12.034

Atherosclerosis
Volume 221, Issue 2 , Pages 366-374, April 2012